Top Medical News
Yesterday
Non-enhanced magnetic resonance imaging (MRI) may be a viable option to ultrasonography for the surveillance of hepatocellular carcinoma (HCC), a new study suggests.
Audrey Abella, 6 days ago
A prospective study has shown the potential of a new algorithm – the FibroScan-AST (FAST) score – to identify patients with nonalcoholic steatohepatitis (NASH) with significant activity and fibrosis.
01 Apr 2020
Patients undergoing hepatic resection are likely to be cured of hepatocellular carcinoma (HCC), with the effect strengthening with increasing recurrence-free time, a new study has shown.
30 Mar 2020
While uncommon, lower gastrointestinal bleeding (LGIB) in patients with cirrhosis appears to worsen mortality risk, a new study has found.
Audrey Abella, 30 Mar 2020
The addition of the epidermal growth factor receptor (EGFR) inhibitor cetuximab (CTX) to chemotherapy (CT) did not offer an overall survival (OS) benefit in patients with resectable colorectal liver metastasis (CRLM) compared with CT alone, updated results of the New EPOC trial has shown.
Tristan Manalac, 16 Mar 2020
Prehabilitation programmes (PPs) appear to improve outcomes in patients undergoing elective liver resection (LR), according to a recent Singapore study.
12 Mar 2020
Earlier normalization of serum alanine aminotransferase (ALT) levels in patients with chronic hepatitis B (CHB) who initiated treatment with entecavir or tenofovir correlates with a proportionally lower risk of hepatocellular carcinoma (HCC), regardless of fatty liver or cirrhosis at baseline and on-treatment virological response (VR), according to a recent study.
Special Reports
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
Roshini Claire Anthony, 10 May 2019

Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress (ILC 2019) showed.

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Audrey Abella, 25 Apr 2019
Patients with chronic hepatitis B virus (HBV) infection treated with the nucleot(s)ide analogue tenofovir disoproxil fumarate (TDF) had a lower risk of hepatocellular carcinoma (HCC) than those treated with entecavir, according to data from a large observational study presented at ILC 2019.
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download